Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics progresses medicinal cannabis brain cancer research

Data from this research can be used as the basis for any future clinical trials.
medicinal cannabis leaf with green tablets
Dr Richard Hopkins will start as managing director commencing 1 July 2018

Zelda Therapeutics Ltd (ASX:ZLD) continues to progress its paediatric (children) brain cancer research project with the Telethon Kids Institute in Perth, Western Australia.

The research project is focused on the pre-clinical testing of Zelda’s compounds, formulations and protocols on pediatric medulloblastoma cell lines.

Medulloblastoma is a common brain tumour in children and accounts for about 15% of brain cancers in children.

Cannabinoids are having an anticancer effect

Initial results have shown that increasing doses of pure ∆9 tetrahydrocannabinol (THC) or pure cannabidiol (CBD) reduces cancer cell viability in cell-based assays.

That means the cannabinoids are having an anticancer effect by reducing the proliferation of cancer cells.

Furthermore, high doses of THC and CBD in combination with cyclophosphamide (a type of chemotherapy agent) shows an increase in antiproliferative effect.

Additional studies are planned to further understand the nature of this effect.

READ: Zelda Therapeutics attracts experienced biopharmaceutical managing director

Zelda’s chairman Harry Karelis said: “We are very pleased to show that pure cannabinoids have demonstrated anti-cancer effect in these assays which gives us confidence that our systems are working well.

“We look forward to the results from the next phase of our research which will test the effectiveness of our formulations on these same assays providing rigorous comparative data as well as in in vivo models.”

Next phase testing full plant extracts

The next phase of the research project will be testing Zelda’s full plant extracts in these same assays and hoping to achieve better results than the individual pure cannabinoids.

At the same time, these full plant extracts will be tested in animal models hosting human tumours to determine the extent of any anti-cancer effect in these in vivo models.

These in vivo studies will generate invaluable data on the potential for cannabinoids to play a role in future cancer therapy regimes.

View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

x-ray
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use